product name AEBSF HCl
Description: AEBSF HCl is a broad spectrum, covalently binding irreversible inhibitor of serine protease including trypsin, chymotrypsin, plasmin and thrombin. AEBSF was found to inhibit Aβ production in various cell lines. In K293 cells transfected with APP695 (K695sw), AEBSF showed does-dependent reduction of Aβ with IC50 value of about 1mM. In HS695 and SKN695 cells transfected with wild-type APP695, AEBSF showed inhibition effect with IC50 value of about 300 μM.
References: J Leukoc Biol. 1996 Sep;60(3):328-36; J Antimicrob Chemother. 2002 May;49(5):871-4; Contraception. 2011 Dec;84(6):642-8.
239.69
Formula
C8H11ClFNO2S
CAS No.
30827-99-7
Storage
-20℃ for 3 years in powder form
-80℃ for 2 years in solvent
Solubility (In vitro)
DMSO: 47 mg/mL (196.1 mM)
Water: 20 mg/mL (83.4 mM)
Ethanol: 47 mg/mL (196.1 mM)
Solubility (In vivo)
Synonyms
other peoduct :
| In Vitro |
In vitro activity: AEBSF inhibits the constitutive production of Aβ by directly inhibiting β-secretase in five different human cell lines, both neural and nonneural. AEBSF, as a serine protease inhibitor, inhibits the lysis of leukemic cells by human macrophages without inhibiting macrophage secretion of TNF-α and IL-1β. AEBSF also disturbs the growth of blastocysts on endometrial cells and inhibit the adhesion of HeLa cells on HUVECs by altering the protein secretion pattern Kinase Assay: Cell Assay: AEBSF was found to inhibit Aβ production in various cell lines. In K293 cells transfected with βAPP695 (K695sw), AEBSF showed dose-dependent reduction of Aβ with the IC50 value of about 1 mM. In HS695 and SKN695 cells transfected with wild-type APP695, AEBSF showed inhibition effect with IC50 value of about 300 μM. AEBSF was also found to increase α-cleavege and inhibit β- cleavage. |
|---|---|
| In Vivo | AEBSF (76.8 mg/kg daily i.p.) results in prolongation of the survival of mice that have been given a lethal T. gondii infection. AEBSF also reduces airway response and underlying inflammation in cockroach allergen-induced murine model. |
| Animal model | Mice infected by a lethal T. Gondii |
| Formulation & Dosage | Formulated in 0.89% saline; 76.8 mg/kg daily; i.p. injection |
| References | J Leukoc Biol. 1996 Sep;60(3):328-36; J Antimicrob Chemother. 2002 May;49(5):871-4; Contraception. 2011 Dec;84(6):642-8. |
